LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a clinical-stage biotechnology company to develop an intra-articular (IA) delivery model in the GastroPlus® Additional Dosage Routes Module.
“We are very pleased to announce this collaboration, which will enhance the GastroPlus physiologically based biopharmaceutics (PBBM)/physiologically based pharmacokinetic (PBPK) model for drug dosing into joints through IA injection products,” said Viera Lukacova, director of Simulation Sciences for Simulations Plus. “Leveraging the data and scientific expertise of our partner, we intend to incorporate a mechanistic model for different species and population groups that will allow for efficient evaluation of IA injection strategies. This will provide a framework to support similar approaches for other drugs.”
John DiBella, Lancaster division president for Simulations Plus, added: “These agreements help to extend the industry leading capabilities of our software tools, while at the same time increasing the investment that Simulations Plus contributes toward new research initiatives. Also, similar to other collaborations which funded development of the numerous dosing models in the GastroPlus Additional Dosage Routes Module, Simulations Plus maintains the right to license the new functionality to all clients, creating additional revenue streams. We look forward to continued interactions with our partners to drive advances to the GastroPlus platform and share the outcomes with the global scientific community.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading provider for physiologically based pharmacokinetic modeling and simulation. Visit us online www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.